Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 4/2009

01-09-2009 | Original Article

Pro-apoptotic and cytostatic activity of naturally occurring cardenolides

Authors: Elena Bloise, Alessandra Braca, Nunziatina De Tommasi, Maria Antonietta Belisario

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2009

Login to get access

Abstract

Purpose

Cardenoliddes are steroid glycosides which are known to exert cardiotonic effects by inhibiting the Na+/K+-ATPase. Several of these compounds have been shown also to possess anti-tumor potential. The aim of the present work was the characterization of the tumor cell growth inhibition activity of four cardenolides, isolated from Periploca graeca L., and the mechanisms underlying such an effect.

Methods

The pro-apoptotic and cytostatic effect of the compounds was tested in U937 (monocytic leukemia) and PC3 (prostate adenocarcinoma). Characterization of apoptosis and cell cycle impairment was obtained by cytofluorimetry and WB.

Results

Periplocymarin and periplocin were the most active compounds, periplocymarin being more effective than the reference compound ouabain. The reduction of cell number by these two cardenolides was due in PC3 cells mainly to the activation of caspase-dependent apoptotic pathways, while in U937 cells to the induction of cell cycle impairment without extensive cell death. Interestingly, periplocymarin, at cytostatic but non-cytotoxic doses, was shown to sensitize U937 cells to TRAIL.

Conclusions

Taken together, our data outline that cardiac glycosides are promising anticancer drugs and contribute to the identification of new natural cardiac glycosides to obtain chemically modified non-cardioactive/low toxic derivatives with enhanced anticancer potency.
Literature
1.
go back to reference Hauptmann PJ, Garg R, Kelly RA (1999) Cardiac glycosides in the next millennium. Prog Cardiovasc Dis 41:247–254CrossRef Hauptmann PJ, Garg R, Kelly RA (1999) Cardiac glycosides in the next millennium. Prog Cardiovasc Dis 41:247–254CrossRef
2.
3.
go back to reference Xie Z, Cai T (2003) Na+/K+-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interv 3:157–168PubMedCrossRef Xie Z, Cai T (2003) Na+/K+-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interv 3:157–168PubMedCrossRef
4.
go back to reference Aperia A (2007) New roles for an old enzyme: Na+/K+-ATPase emerges as an interesting drug target. J Intern Med 261:44–52PubMedCrossRef Aperia A (2007) New roles for an old enzyme: Na+/K+-ATPase emerges as an interesting drug target. J Intern Med 261:44–52PubMedCrossRef
5.
go back to reference Newman RA, Yang P, Pawlus AD, Block KI (2008) Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8:36–49PubMedCrossRef Newman RA, Yang P, Pawlus AD, Block KI (2008) Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8:36–49PubMedCrossRef
6.
go back to reference Huang YT, Chueh SC, Teng CM, Guh JH (2004) Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol 67:727–733PubMedCrossRef Huang YT, Chueh SC, Teng CM, Guh JH (2004) Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol 67:727–733PubMedCrossRef
7.
go back to reference Bielawski K, Winnicka K, Bielawska A (2006) Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull 29:1493–1497PubMedCrossRef Bielawski K, Winnicka K, Bielawska A (2006) Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull 29:1493–1497PubMedCrossRef
8.
go back to reference Ramirez-Ortega M, Maldonado-Lagunas V, Melendez-Zajgla J, Carrillo-Hernandez JF, Pastelín-Hernandez G, Picazo-Picazo O, Ceballos-Reyes G (2006) Proliferation and apoptosis of HeLa cells induced by in vitro stimulation with digitalis. Eur J Pharmacol 534:71–76PubMedCrossRef Ramirez-Ortega M, Maldonado-Lagunas V, Melendez-Zajgla J, Carrillo-Hernandez JF, Pastelín-Hernandez G, Picazo-Picazo O, Ceballos-Reyes G (2006) Proliferation and apoptosis of HeLa cells induced by in vitro stimulation with digitalis. Eur J Pharmacol 534:71–76PubMedCrossRef
9.
go back to reference Kulikov A, Eva A, Kirch U, Boldyrev A, Scheiner-Bobis G (2007) Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim Biophys Acta 1768:1691–1702PubMedCrossRef Kulikov A, Eva A, Kirch U, Boldyrev A, Scheiner-Bobis G (2007) Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim Biophys Acta 1768:1691–1702PubMedCrossRef
10.
go back to reference Larre I, Ponce A, Fiorentino R, Shoshani L, Contreras RG, Cereijido M (2006) Contacts and cooperation between cells depend on the hormone ouabain. Proc Natl Acad Sci USA 103:10911–10916PubMedCrossRef Larre I, Ponce A, Fiorentino R, Shoshani L, Contreras RG, Cereijido M (2006) Contacts and cooperation between cells depend on the hormone ouabain. Proc Natl Acad Sci USA 103:10911–10916PubMedCrossRef
11.
go back to reference Stenkvist B, Pengtsson E, Dahlqvist B, Eriksson O, Jarkrans T, Nordin B (1982) Cardiac glycosides and breast cancer, revisited. N Engl J Med 306:484PubMed Stenkvist B, Pengtsson E, Dahlqvist B, Eriksson O, Jarkrans T, Nordin B (1982) Cardiac glycosides and breast cancer, revisited. N Engl J Med 306:484PubMed
12.
go back to reference Haux J, Klepp O, Spigset O, Tretli S (2001) Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 1:11PubMedCrossRef Haux J, Klepp O, Spigset O, Tretli S (2001) Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 1:11PubMedCrossRef
13.
go back to reference Repke KHR, Benga GH, Tager JM (1988) Biomembranes, basic and medical research. Springer, Berlin, pp 161–173 Repke KHR, Benga GH, Tager JM (1988) Biomembranes, basic and medical research. Springer, Berlin, pp 161–173
14.
go back to reference Langenhan JM, Peters NR, Guzei IA, Hoffmann FM, Thorson JS (2005) Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization. Proc Natl Acad Sci USA 102:12305–12310PubMedCrossRef Langenhan JM, Peters NR, Guzei IA, Hoffmann FM, Thorson JS (2005) Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization. Proc Natl Acad Sci USA 102:12305–12310PubMedCrossRef
15.
go back to reference Daniel D, Süsal C, Kopp B, Opelz G, Terness P (2003) Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol 3:1791–1801PubMedCrossRef Daniel D, Süsal C, Kopp B, Opelz G, Terness P (2003) Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol 3:1791–1801PubMedCrossRef
16.
go back to reference López-Lázaro M (2007) Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 11:1043–1053PubMedCrossRef López-Lázaro M (2007) Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 11:1043–1053PubMedCrossRef
17.
go back to reference Spera D, Siciliano T, De Tommasi N, Braca A, Vessières A (2007) Antiproliferative cardenolides from Periploca graeca. Planta Med 73:384–387PubMedCrossRef Spera D, Siciliano T, De Tommasi N, Braca A, Vessières A (2007) Antiproliferative cardenolides from Periploca graeca. Planta Med 73:384–387PubMedCrossRef
18.
go back to reference Jortani SA, Helm RA, Valdes R Jr (1996) Inhibition of Na+/K+-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays. Clin Chem 42:1654–1658PubMed Jortani SA, Helm RA, Valdes R Jr (1996) Inhibition of Na+/K+-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays. Clin Chem 42:1654–1658PubMed
19.
go back to reference Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271–279PubMedCrossRef Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271–279PubMedCrossRef
20.
go back to reference Scaduto RC Jr, Grotyohann LW (1999) Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 76:469–477PubMedCrossRef Scaduto RC Jr, Grotyohann LW (1999) Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 76:469–477PubMedCrossRef
21.
go back to reference Dal Piaz F, Nigro P, Braca A, De Tommasi N, Belisario MA (2007) 13-Hydroxy-15-oxo-zoapatlin, an ent-kaurane diterpene, induces apoptosis in human leukemia cells, affecting thiol-mediated redox regulation. Free Radic Biol Med 43:1409–1422PubMedCrossRef Dal Piaz F, Nigro P, Braca A, De Tommasi N, Belisario MA (2007) 13-Hydroxy-15-oxo-zoapatlin, an ent-kaurane diterpene, induces apoptosis in human leukemia cells, affecting thiol-mediated redox regulation. Free Radic Biol Med 43:1409–1422PubMedCrossRef
22.
go back to reference Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184:39–51PubMedCrossRef Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184:39–51PubMedCrossRef
23.
go back to reference Gogvadze V, Orrenius S (2006) Mitochondrial regulation of apoptotic cell death. Chem Biol Interact 163:4–14PubMedCrossRef Gogvadze V, Orrenius S (2006) Mitochondrial regulation of apoptotic cell death. Chem Biol Interact 163:4–14PubMedCrossRef
24.
go back to reference Almasan A, Ashkenazi A (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14:337–348PubMedCrossRef Almasan A, Ashkenazi A (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14:337–348PubMedCrossRef
25.
go back to reference MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12:773–782PubMedCrossRef MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12:773–782PubMedCrossRef
26.
go back to reference Mijatovic T, De Nève N, Gailly P, Mathieu V, Haibe-Kains B, Bontempi G, Lapeira J, Decaestecker C, Facchini V, Kiss R (2008) Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol Cancer Ther 7(5):1285–1296PubMedCrossRef Mijatovic T, De Nève N, Gailly P, Mathieu V, Haibe-Kains B, Bontempi G, Lapeira J, Decaestecker C, Facchini V, Kiss R (2008) Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol Cancer Ther 7(5):1285–1296PubMedCrossRef
27.
go back to reference Ihenetu K, Qazzaz HM, Crespo F, Fernandez-Botran R, Valdes R (2007) Digoxin-like immunoreactive factors induce apoptosis in human acute T-cell lymphoblastic leukemia. J Clin Chem 53:1315–1322CrossRef Ihenetu K, Qazzaz HM, Crespo F, Fernandez-Botran R, Valdes R (2007) Digoxin-like immunoreactive factors induce apoptosis in human acute T-cell lymphoblastic leukemia. J Clin Chem 53:1315–1322CrossRef
28.
30.
go back to reference Wasserstrom JA, Aistrup GL (2005) Digitalis: new actions for an old drug. Am J Physiol Heart Circ Physiol 289:H1781–H1793PubMedCrossRef Wasserstrom JA, Aistrup GL (2005) Digitalis: new actions for an old drug. Am J Physiol Heart Circ Physiol 289:H1781–H1793PubMedCrossRef
31.
go back to reference Gilmore-Hebert M, Schneider JW, Greene AL, Berliner N, Stolle CA, Lomax K, Mercer RW, Benz EJ Jr (1989) Expression of multiple Na+, K+-adenosine triphosphatase isoform genes in human hematopoietic cells. Behavior of the novel A3 isoform during induced maturation of HL60 cells. J Clin Invest 84:347–351PubMedCrossRef Gilmore-Hebert M, Schneider JW, Greene AL, Berliner N, Stolle CA, Lomax K, Mercer RW, Benz EJ Jr (1989) Expression of multiple Na+, K+-adenosine triphosphatase isoform genes in human hematopoietic cells. Behavior of the novel A3 isoform during induced maturation of HL60 cells. J Clin Invest 84:347–351PubMedCrossRef
32.
go back to reference Duran MJ, Chosseler M, Pressley T (2004) Regulation of Na, K-pump-mediated transport by prolactin in cultured human prostate epithelial cells. Cell Mol Biol 50:809–814PubMed Duran MJ, Chosseler M, Pressley T (2004) Regulation of Na, K-pump-mediated transport by prolactin in cultured human prostate epithelial cells. Cell Mol Biol 50:809–814PubMed
33.
go back to reference Raghavendra PB, Sreenivasan Y, Manna SK (2007) Oleandrin induces apoptosis in human, but not in murine cells: dephosphorylation of Akt, expression of FasL, and alteration of membrane fluidity. Mol Immunol 44:2292–2302PubMedCrossRef Raghavendra PB, Sreenivasan Y, Manna SK (2007) Oleandrin induces apoptosis in human, but not in murine cells: dephosphorylation of Akt, expression of FasL, and alteration of membrane fluidity. Mol Immunol 44:2292–2302PubMedCrossRef
34.
go back to reference Kometiani P, Liu L, Askari A (2005) Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. Mol Pharmacol 67:929–936PubMedCrossRef Kometiani P, Liu L, Askari A (2005) Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. Mol Pharmacol 67:929–936PubMedCrossRef
35.
go back to reference Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, Tyrrell DL, Kneteman NM (2004) TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64:8502–8506PubMedCrossRef Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, Tyrrell DL, Kneteman NM (2004) TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64:8502–8506PubMedCrossRef
36.
go back to reference MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM (2002) Mechanisms of resistance to TRAIL induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21:6809–6818PubMedCrossRef MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM (2002) Mechanisms of resistance to TRAIL induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21:6809–6818PubMedCrossRef
37.
go back to reference Todaro M, Lombardo Y, Francipane MG, Alea MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrusa A, Condorelli G, Walczak H, Stassi G (2008) Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 15:762–772PubMedCrossRef Todaro M, Lombardo Y, Francipane MG, Alea MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrusa A, Condorelli G, Walczak H, Stassi G (2008) Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 15:762–772PubMedCrossRef
38.
go back to reference Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA (2006) Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 66:5867–5874PubMedCrossRef Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA (2006) Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 66:5867–5874PubMedCrossRef
39.
go back to reference Rosato RR, Almenara JA, Coe S, Grant S (2007) The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 67:9490–9500PubMedCrossRef Rosato RR, Almenara JA, Coe S, Grant S (2007) The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 67:9490–9500PubMedCrossRef
40.
go back to reference Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11(Suppl 2):S193–S206PubMedCrossRef Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11(Suppl 2):S193–S206PubMedCrossRef
41.
go back to reference Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E (2007) Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 12:1533–1541PubMedCrossRef Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E (2007) Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 12:1533–1541PubMedCrossRef
Metadata
Title
Pro-apoptotic and cytostatic activity of naturally occurring cardenolides
Authors
Elena Bloise
Alessandra Braca
Nunziatina De Tommasi
Maria Antonietta Belisario
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-0929-5

Other articles of this Issue 4/2009

Cancer Chemotherapy and Pharmacology 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine